Prevention of high risk corneal graft rejection using cyclosporine A (CsA) incorporated into a collagen matrix

Ocular Immunology and Inflammation

Volumn 5, Issue 2, 1997, Pages 101-110

  Mahlberg, Kaj ^b   Uusitalo, Risto J ^a   Oksala, Olli ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Oy Leiras Finland Ab   (Finland)

Author keywords

Animal model for high risk keratoplasty; Collagen fragments; Collagen shields; Cyclosporine

Indexed keywords

COLLAGEN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORNEA TRANSPLANTATION; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; HISTOLOGY; KERATOPLASTY; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; SLIT LAMP;

EID: 0030855750     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.3109/09273949709085058     Document Type: Article

References (27)

1. Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976;6:468-475.
2. Gluckman E, Devergie A, Lokiec F. Use of cyclosporin for the prevention of graft-versus host disease after allogenic bone marow transplantation. Transplant Proc 1988;20:(No 3, suppl 3):461-469.
3. Berlin MW, Bouchard CS, Franz S, Chmielinska J. Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989;96:1144-1150.
4. Kruit PL, Van Balen AThM, Stilma JS. Cyclosporin A treatment in two cases of corneal peripheral melting syndrome. Doc Ophthalmol 1985;59:33-39.
5. Masuda K, Nakajima A. A double-masked study of cyclosporin treatment in Behcet's disease. In: Schindler R (ed). Cyclosporine in Autoimmune Diseases. 1st International Symposium, Basel, March 18-20, 1985; 162-164. Springer-Verlag, Berlin.
6. Nussenblatt RP, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983;2:235-238.
7. BenEzra D, Cohen E, Rakatomalala M, deCourten C, Harris W, Chajek T, et al. Treatment of endogenous uveitis with cyclosporin A. Transplant Proc 1988;20:(No 3, Suppl 4):122-127.
8. Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989;107:506-510.
9. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short-versus long-term therapy. Ophthalmology 1994;101:128-133.
10. Uusitalo RJ, Mahlberg K, Krootila K, Ruusuvaara P. Systemic cyclosporin treatment for high-risk corneal transplantation. Ocular Immunol and Inflamm 1996;4:15-24.
11. Hess AD, Esa AH, Colombani PH. Mechanism of action of cyclosporine: effects on cells of the immune system and on subcellular events in T cell activation. Transplant Proc 1988;20: (No 2, Suppl 2): 29-40.
12. Vine W, Billiar T, Simmons R, Bowers LD. Cyclosporine-induced hepatotoxicity: a microassay by hepatocytes in tissue culture. Transplant Proc 1988;20 (No 3, Suppl 3): 859-862.
13. Palestine AG, Austin HA III, Balow JE, Antonovych TT, Sabnis SG, Preuss HG, Nussenblatt RB. Renal histopathologic alterations in patients treated with cyclosporin for uveitis. N Engl J Med 1986:314:1293-1298.
14. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988;20 (No 3, Suppl 3):759-771.
15. Hill JC, Maske R. An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation 1986;46:26-30.
16. Mahlberg K, Uusitalo RJ, Gebhardt B, Kaufman HE. Prevention of experimental corneal allograft rejection in rabbits using cyclosporin-collagen shields. Graefe's Arch Clin Exp Ophthalmol 1991;229:69-74.
17. Haaskjold E, Öhrström A, Uusitalo RJ, Krootila K, Sandvig KU, Sönne H, Mahlberg K. Use of collagen shields in cataract surgery. J Cataract Refract Surg 1994;20:150-153.
18. Aquavella JV, Ruffini JJ, LoCascio JA. Use of collagen shields as a surgical adjunct. J Cataract Refract Surg 1988;14:492-495.
19. Poland DE, Kaufman HE. Clinical uses of collagen shields. J Cataract Refract Surg 1988;14:489-491.
20. Sawusch MR, O'Brien TP, Dick JD, Gottsch JD. Use of collagen corneal shield in the treatment of bacterial keratitis. Am J Ophthalmol 1988;106:279-281.
21. Hunter PA, Garner A, Wilhelmus RK, Rice NCS, Jones BR. Corneal graft rejection: a new rabbit model and cyclosporin A. Br J Ophthalmol 1982;66:292-302.
22. Newton C, Gebhardt BM, Kaufman H. Topically applied cyclosporine in Azone prolongs corneal allograft survival. Invest Ophthalmol 1988;29:208-215.
23. Williams KA, Grutzmacher RD, Roussel TJ, Coster DJ. A comparison of the effects of topical cyclosporin and topical steroid on rabbit allograft rejection. Transplantation 1985;39:242-244.
24. Chen YP, Gebhardt BM, Reidy JJ, Kaufman H. Cyclosporine-containing collagen shields suppress corneal allograft rejection. Am J Ophthalmol 1990;109:132-137.
25. Phinney RB, Schwartz SD, Lee DA, Mondino BJ. Collagen-shield delivery of gentamicin and vancomycin. Arch Ophthalmol 1988;106:1599-1604.
26. Gebhardt BM, Varnell ED, Kaufman HE. Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection. J Ocular Pharmacol Therap 1995; 11:509-517.
27. BenEzra D, Mafzir G. Ocular penetration of cyclosporine A. Arch Ophthalmol 1990;108:584-587.